Credit Suisse Ag Igm Biosciences, Inc. Transaction History

Credit Suisse Ag

12 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2023 Aug 11, 2023	SELL	$8.86 - $14.0 $5,351 - $8,456	-604 Reduced 5.39%	10,607 $97,000
Q1 2023 May 10, 2023	BUY	$13.74 - $25.76 $38,788 - $72,720	2,823 Added 33.66%	11,211 $154,000
Q4 2022 Feb 13, 2023	BUY	$15.45 - $26.02 $45,484 - $76,602	2,944 Added 54.08%	8,388 $142,000
Q3 2022 Nov 10, 2022	BUY	$15.42 - $27.01 $832 - $1,458	54 Added 1.0%	5,444 $124,000
Q2 2022 Aug 12, 2022	BUY	$13.27 - $25.5 $71,525 - $137,445	5,390 New	5,390 $98,000
Q4 2021 Feb 14, 2022	SELL	$27.59 - $66.39 $118,857 - $286,008	-4,308 Closed	0 $0
Q3 2021 Nov 12, 2021	BUY	$65.76 - $90.65 $5,589 - $7,705	85 Added 2.01%	4,308 $283,000
Q2 2021 Aug 16, 2021	SELL	$57.98 - $96.6 $108,480 - $180,738	-1,871 Reduced 30.7%	4,223 $351,000
Q1 2021 May 14, 2021	SELL	$71.56 - $121.23 $780,290 - $1.32 Million	-10,904 Reduced 64.15%	6,094 $468,000
Q4 2020 Feb 12, 2021	BUY	$47.41 - $115.03 $220,124 - $534,084	4,643 Added 37.58%	16,998 $1.5 Million
Q3 2020 Nov 13, 2020	SELL	$43.0 - $84.01 $48,719 - $95,183	-1,133 Reduced 8.4%	12,355 $911,000
Q2 2020 Aug 12, 2020	BUY	$51.3 - $75.21 $691,934 - $1.01 Million	13,488 New	13,488 $985,000

20.7M

68K

52.2K

Ticker IGMS
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 28,969,000
Market Cap $214M
Description
IGM Biosciences, Inc., a biotechnology company, develops Immunoglobulin M (IgM) antibodies for the treatment of cancer, infectious diseases, and autoimmune and inflammatory diseases. The company's lead product candidate is IGM-2323, a bispecific IgM antibody that is in Phase 2 clinical trials to treat patients with relapsed/refractory B cell Non...

Get notified when there are updates to the investment portfolio of Credit Suisse Ag, based on Form 13F filings with the SEC.

Stay updated on Credit Suisse Ag with notifications on news.